Floatz logo

Milatuzumab

NHL

Gilead Sciencesmonoclonal_antibodyPhase 1/2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the NHL cohort.

Asset / SponsorPhaseRating
Isatuximab
Indapta Therapeutics, INC.
Phase 2B
Veltuzumab
Gilead Sciences
Phase 1/2B
FALLYPRIDE
National Cancer Institute (NCI)
Phase 1/2CCC
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
National Cancer Institute (NCI)
Phase 1/2CCC
Axi-Cel
University Medical Center Groningen
Phase 2CCC

View all 32 →

Same molecule, other indications

Milatuzumab is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
Lymphoma, Large-CellDormant
CCC
Indicative ·
51 / 100
View asset →
Lymphoma, Intermediate-GradeDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →